1st Group Ltd. (AU:VFX)
ASX:VFX
Want to see AU:VFX full AI Analyst Report?
Top Page
1st Group Ltd.
(Sydney:VFX)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.06
▼(-43.00% Downside)
Action:ReiteratedDate:04/24/26
The score is driven primarily by weak financial performance—deep losses, negative equity, and ongoing cash burn—indicating elevated operational and funding risk. Technical indicators also reflect a bearish trend (price below key moving averages and negative MACD), while valuation is hindered by a negative P/E and no dividend support.
Positive Factors
Revenue Growth
Reported revenue growth, including a large jump in 2025, indicates demand traction and top-line scalability potential. If sustained, higher revenue can enable operating leverage, help absorb fixed costs, and create a clearer path to profitability over a multi-quarter horizon.
Negative Factors
Negative Shareholder Equity
Persistent negative shareholder equity signals a structural capital shortfall that limits strategic options. It increases reliance on external funding, heightens dilution risk, and constrains the ability to absorb shocks or invest, making durable recovery dependent on sizeable capital or sustained profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Reported revenue growth, including a large jump in 2025, indicates demand traction and top-line scalability potential. If sustained, higher revenue can enable operating leverage, help absorb fixed costs, and create a clearer path to profitability over a multi-quarter horizon.
Read all positive factors
1st Group Ltd. (VFX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.76M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)1.63
Revenue Growth-5.32%
EPS Growth72.83%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.05
Shares Outstanding86,606,830
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-3.39
Price to Sales (P/S)1.48
P/FCF Ratio-1.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
1st Group Ltd. Business Overview & Revenue Model
Company Description
Visionflex Group Limited, together its subsidiaries, engages in the provision of healthcare, telehealth, and remote diagnostic solutions in Australia. The company offers virtual healthcare solutions and peripheral medical devices that integrate in...
How the Company Makes Money
null...
1st Group Ltd. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 4.19M | 6.65M | 4.47M | 4.83M |
| Gross Profit | -2.42M | 3.94M | 3.41M | 4.83M |
| EBITDA | -3.37M | -1.32M | -3.56M | -6.43M |
| Net Income | -3.19M | -1.83M | -3.66M | -6.82M |
Balance Sheet | ||||
| Total Assets | 3.39M | 2.88M | 4.09M | 4.27M |
| Cash, Cash Equivalents and Short-Term Investments | 1.89M | 1.16M | 1.44M | 2.01M |
| Total Debt | 2.47M | 13.65M | 12.11M | 4.65M |
| Total Liabilities | 5.22M | 19.76M | 18.73M | 8.16M |
| Stockholders Equity | -1.82M | -8.11M | -6.74M | -3.89M |
Cash Flow | ||||
| Free Cash Flow | -3.19M | -1.38M | -3.68M | -2.82M |
| Operating Cash Flow | -3.16M | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | -29.51K | 276.80K | 720.13K | -21.84K |
| Financing Cash Flow | 3.92M | 798.81K | 2.36M | 4.59M |
1st Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$11.48M | -1.00 | -218.76% | ― | 76.94% | 42.95% | |
41 Neutral | AU$4.76M | -1.94 | 245.46% | ― | -5.32% | 72.83% | |
41 Neutral | AU$3.65M | -1.98 | 20.02% | ― | -5.76% | 8.00% | |
41 Neutral | AU$10.14M | -1.62 | -44.35% | ― | -32.09% | 34.85% | |
41 Neutral | AU$9.83M | -0.96 | 152.58% | ― | -57.91% | -9.02% |
* Healthcare Sector Average
AU:VFX
1st Group Ltd.
0.06
-0.02
-27.63%
AU:GLH
Global Health Limited
0.06
-0.03
-32.61%
AU:EVE
EVE Health Group Limited
0.03
>-0.01
-3.33%
AU:CMB
Regeneus Ltd.
0.42
0.20
90.91%
AU:HIQ
HitIQ Limited
0.01
-0.01
-48.00%
1st Group Ltd. Corporate Events
Visionflex Performance Rights Lapse Trims Future Equity Pool
Mar 31, 2026
Visionflex Group Limited has disclosed that 280,000 performance rights, trading under the ASX code VFXAR, have lapsed as of March 31, 2026, after the relevant vesting conditions were not met or were deemed incapable of being satisfied. The cessati...
Visionflex Seeks ASX Quotation for 44,444 New Ordinary Shares
Mar 31, 2026
Visionflex Group Limited has applied for quotation on the ASX of 44,444 new fully paid ordinary shares, to be issued on 31 March 2026 under the code VFX. The shares arise from the exercise or conversion of existing options or other convertible sec...
Visionflex lifts recurring revenue as it shifts to subscription-led telehealth model
Feb 26, 2026
Visionflex reported H1 FY26 revenue of $1.7 million, down 10% on the prior period, but lifted recurring revenue by 29% to $0.9 million, with subscriptions and support now contributing about 52% of total revenue. Annual recurring revenue rose 23% t...
Visionflex Group Releases FY26 Interim Financial Report
Feb 26, 2026
Visionflex Group Limited has released its FY26 Appendix 4D and interim financial report, outlining the company’s consolidated financial statements and directors’ commentary for the period. The report package includes profit and loss, b...
Visionflex Seeks ASX Quotation for Additional Ordinary Shares
Feb 3, 2026
Visionflex Group Limited has applied to the ASX for quotation of 36,110 new fully paid ordinary shares under its existing issuer code VFX. The additional securities arise from the exercise or conversion of existing options or other convertible sec...
Visionflex Options Lapse, Removing Potential Future Dilution
Jan 30, 2026
Visionflex Group Limited has announced the expiry of 9,736,607 unexercised options, each with an exercise price of A$0.35 and an expiry date of 25 January 2026, resulting in the cessation of these securities from its issued capital. The lapse of t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.